Filter Results:
(610)
Show Results For
- All HBS Web
(1,022)
- People (4)
- News (256)
- Research (610)
- Events (9)
- Multimedia (24)
- Faculty Publications (395)
Show Results For
- All HBS Web
(1,022)
- People (4)
- News (256)
- Research (610)
- Events (9)
- Multimedia (24)
- Faculty Publications (395)
Sort by
- 27 Nov 2017
- Research & Ideas
Beware the Lasting Impression of a 'Temporary' Selfie
a prop, or exhibited nudity, drinking, or drug use. As to the impact on observers of the posts, the temporary-sharers were characterized as having worse judgment than those who shared in permanent mediums. That belief was underscored... View Details
Keywords: by Rachel Layne
- 03 Mar 2009
- First Look
First Look: March 3, 2009
Public Interest: Roche & Tamiflu Harvard Business School Case 609-061 The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu.... View Details
Keywords: Martha Lagace
- 08 Jun 2010
- First Look
First Look: June 8
case:http://cb.hbsp.harvard.edu/cb/product/810123-PDF-ENG Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration Karim R. Lakhani and Paul R. CarlileHarvard Business School Case 610-074 This case presents the Myelin... View Details
Keywords: Martha Lagace
- 09 Apr 2012
- Research & Ideas
Who Sways the USDA on GMO Approvals?
Other Agencies Influence Approvals In the case of procedural legitimacy, the researchers found a strong influence from an unlikely source—the USDA's sister agency, the Food and Drug Administration. In the process of approving GMOs,... View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
benefits of sharing data, which can then be used to more quickly identify the most pressing targets and design trials to address them. Innovations to the typical clinical trial model are also being used. In an adaptive platform trial, for example, different View Details
- 10 Sep 2008
- Research & Ideas
Long-Tail Economics? Give Me Blockbusters!
by focusing on bigger films that require a bigger commitment." Jeff Robinov believes in blockbusters and his strategy is to create more of them. The pharmaceutical and entertainment industries are similar. R&D costs in both are high. Results are unpredictable.... View Details
- 15 Jun 2016
- Research & Ideas
These VC Partners May Make Your Firm Less Innovative
developed by the Food and Drug Administration (FDA), they were able to tell which companies were competitors in the same patient application areas (such as cardiology, oncology, or urology) and product classes. Then, using commercial... View Details
- 25 Aug 2015
- First Look
First Look Tuesday
to examine the phenomena in the context of health. In particular, we examine how an individual's prior experiences and the experiences of those around them alter the operational decisions that the individual makes. We draw on an exogenous announcement of negative news... View Details
- 05 Nov 2007
- Research & Ideas
The Changing Face of American Innovation
on? Are they concentrated in a specific industry or business type? A: Inventors can file for patents in many technology fields, ranging from chemicals and drugs to computer software to agricultural machinery. Immigrant contributions are... View Details
- 15 Dec 2014
- Research & Ideas
Deconstructing the Price Tag
expenses incurred. For example, R&D expenditures in the pharmaceutical industry involve more than just the cost of producing one particular drug. Many drugs may have to fail before one succeeds, and that one hit View Details
- 08 Mar 2016
- First Look
March 8, 2016
cultural model and undermine their own positions with inappropriate use of symbolic market-creation actions. Download working paper: https://www.hbs.edu/faculty/Pages/item.aspx?num=50701 Harvard Business School Case 916-026 Express Scripts: Promoting Prescription View Details
Keywords: Sean Silverthorne
- 25 Oct 2016
- First Look
October 25, 2016
insulate consumers from cost sharing, thereby undermining insurers’ ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry between 2007 and... View Details
Keywords: Sean Silverthorne
- 07 Aug 2007
- First Look
First Look: August 7, 2007
and issues around current practices. Purchase this note: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=807124 U.S. Food and Drug Administration Harvard Business School Note 807-050 Describes the U.S. FDA with particular... View Details
Keywords: Martha Lagace
- 20 May 2016
- Op-Ed
World Health Organization Lacks Leadership to Combat Pandemics
greater role in WHO governance and if there are guarantees of purchase contracts for new drugs and vaccines at sensible prices. Both seem unlikely, as the WHO's culture has always winced at cooperation with the private sector. WHO's track... View Details
- 14 Jul 2006
- Op-Ed
The Case for Consumer-Driven Medicaid
diabetic and asthmatic enrollees due to increased testing and drug utilization, while management consulting firm McKinsey found that consumer-driven enrollees were more likely to "very carefully follow treatment regimens for chronic... View Details
Keywords: by Regina E. Herzlinger
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
actions was not without risk for the CEOs and their companies” While many CEOs prefer to stay under the radar and avoid public scrutiny, Ken Frazier led the way with his example. As the chair of PhRMA, the pharmaceutical manufacturers association, Frazier has led the... View Details
Keywords: by Bill George
- 18 Apr 2017
- First Look
First Look at New Ideas, April 18
M&A) and Werner Baumann (CFO) have to decide whether to increase the cash portion of their $14.2 billion offer and/or amend the terms of a proposed joint venture (JV) with Merck involving cardiovascular drugs that had been included in... View Details
Keywords: by Sean Silverthorne
- 20 Dec 2018
- Research & Ideas
Most Popular Stories and Research Papers of 2018
Cirrus Foroughi, and Barbara Larson. Developing Novel Drugs This paper by Joshua Krieger and colleagues contributes to our understanding of how financing constraints affect the direction of innovation in View Details
Keywords: by Sean Silverthorne
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
he made the decision to continue investing in longer-term research rather than short-term profit after Merck took its blockbuster drug Vioxx off the market in September 2004. "He believed that the only way for Merck to recover was to... View Details
- 27 Jan 2003
- Research & Ideas
New Cluster Mapping Project Helps Companies Locate Facilities
A: There is some heartening progress. The word is out among retailers about the under-served market in inner cities. Drug chains, such as Walgreen's, and many other retailers, such as Home Depot, are pursuing this opportunity to good... View Details
Keywords: by Sean Silverthorne